CRPC
CRPC
Metastatic castration-resistant prostate cancer
Advertisement
Katy MarshallCRPC | September 9, 2024
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
Read More
Emily MenendezCRPC | August 30, 2024
Enzalutamide was associated with improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate.
Katy MarshallCRPC | August 22, 2024
The study presented the results of cohorts 4 and 5 from the phase 2 KEYNOTE-199 study.
Emily MenendezCRPC | August 2, 2024
The impact of potential comorbidities and concomitant medication interactions in ARPIs are not well understood.
Emily MenendezCRPC | July 10, 2024
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
Vishnu MurthyCRPC | July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Katy MarshallCRPC | June 21, 2024
The study’s primary end points were the incidence of all-grade or grade 3 and higher cardiovascular events.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Oliver Sartor, MDRLT | June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Geoffrey Johnson, MD, PhDRLT | June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Pedro Barata, MDCRPC | June 13, 2024
Dr. Pedro Barata discusses his research letter examining patterns of HRR mutation genetic testing in men with mCRPC.
Emily MenendezProstate Cancer | June 13, 2024
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Emily MenendezCRPC | June 13, 2024
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Alicia Morgans, MD, MPHCRPC | June 12, 2024
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Zachary BessetteRLT | June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Brandon TwyfordCRPC | June 10, 2024
The PSMAfore trial shows [177Lu]Lu-PSMA-617 significantly improves rPFS, ORR, and PSA50 in taxane-naive patients with mCRPC.
Samuel Denmeade, MDCRPC | June 6, 2024
Dr. Denmeade highlights his research on blood-based markers of differential efficacy of BAT and enzalutamide in TRANSFORMER.
GU Oncology Now EditorsAdvancements in Oncology | June 13, 2024
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
Soumyajit Roy, MDCRPC | June 6, 2024
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Advertisement
Advertisement
Advertisement